AorTech AGM Statement

RNS Number : 1237Z

Aortech International PLC

16 September 2009

 



For Immediate Release

September 16, 2009

AorTech AGM Statement

At the Annual General Meeting of AorTech International plc to be held 16 September 2009,

Chairman Jon Pither will make the following statement:

'Polymer and manufactured component volume and revenue continue to grow as a consequence of the maturation of existing licenses and the addition of new ones. Now entering its fourth year of long term implant use, the performance of Elast-Eon™ polymers continues to be defect-free. These implants now number in the millions and are comprised of a growing spectrum of applications.  

'We are particularly excited about the progress of our component business. From our 25,000 square foot ISO certified manufacturing facility we are now routinely shipping various components for spinal disc and circulatory support devices. Our entry into the $100m header market will be punctuated by first human use in 2010 and we are in the late stages of qualifying our polymer heart valve technology for use in circulatory support devices.  

'There have been no significant changes in the financial position of the Company since 31 March

2009.'

The twelfth Annual General Meeting of AorTech International plc will be held in the Mansfield Room of the Marriott Hotel Chancery Court, 252 High Holborn, London WC1V 7EN on 16 September 2009 at 12:00 noon.

- Ends -

For further information please contact:

AorTech International plc

Frank Maguire, Chief Executive

Tel: + 1 801 201 4336

Evolution Securities
Bobbie Hilliam / Chris Clarke

Tel: [phone]

AorTech International plc

Sarah Price, Investor Relations

Tel: + 1 801 550 4349

e-mail [e-mail]

Notes to Editors:

About AorTech International plc

AorTech is the developer and manufacturer of Elast-Eon the world's leading biostable implantable silicone-urethane copolymer. The company is publicly listed in the UK on the Alternative Investment Market exchange (AIM:AOR) with dedicated sales and market development specialists in the US, and its 25,000 square foot ISO-Certified Technology and Biomaterials Manufacturing Center located in Melbourne, Australia.

For additional information go to: www.aortech.com

 

END

 

 

AGMGUUPUBUPBGBA